TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Effectiveness of Sepraspray™ in Reducing Post-surgical Adhesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are scheduled to undergo a total proctocolectomy and a pelvic pouch with diverting ileostomy.~Exclusion Criteria:~* Patients who are pregnant.~* Patients with ongoing abdominal abscess.~* Patients with ongoing bacterial peritonitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sepraspray (Type: EXPERIMENTAL): Sepraspray Powder applied on the viscera directly under the midline incision followed by incision closure. Sepraspray dose applied was between 2 g and 4 g per patient.
- Control (Type: NO_INTERVENTION): No anti-adhesion treatment used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent~* ECOG/Zubrod/SWOG Performance Status \< 2~* Life expectancy \> 12 weeks~* Male or female' age \>18 years Subjects of childbearing potential must be using an effective means of contraception.~* Histologic diagnosis of HCC or cholangiocarcinoma that is locally advanced but cannot be treated adequately by radiotherapy or surgery (more than one lesion, portal vein involvement, or poor hepatic reserve); or metastatic disease or an AFB \> 20 w/CT scan consistent with HCC~* Renal function: Serum creatinine \< 2.0 mg/dl~* Serum calcium \< 12 mg/dl~* Serum electrolytes, including magnesium and potassium, within normal limits~Exclusion Criteria:~* Pregnant or lactating females~* Myocardial infarction or ischemia within the 6 months before Cycle 0' Day 0~* Uncontrolled' clinically significant dysrhythmia~* Known left ventricular Ejection Fraction below the normal limit for UTMB~* History of prior malignancy within the prior five years, with the exception of non-melanoma carcinomas of the skin, and carcinoma in situ of the cervix~* More than one prior chemotherapy regimens for liver cancer (subjects who are receiving antineoplastic agents for non-malignant conditions, such as methotrexate for rheumatoid arthritis, must be off such therapy for at least four weeks prior to receiving the first dose of protocol therapy, and may not receive such therapy while participating in this protocol)~* Receiving any other chemotherapy or cytokine therapy~* Subjects receiving radiation therapy (Trisenox will be held during the administration of palliative or emergent radiotherapy)~* Subjects who have received radiofrequency ablation or hepatic arterial embolization within the past four weeks (patients who have received prior RFA or HAE are otherwise eligible)~* Prior radiotherapy to an indicator lesion unless there is objective evidence of tumor growth in that lesion~* Uncontrolled metastatic disease of the central nervous system~* Prior and on-going Grade 2-4 peripheral neuropathy, as measured by NCI Common Toxicity Criteria version 3.0~* Radiotherapy within the 2 weeks before Cycle 1' Day 1~* Surgery within the 2 weeks before Cycle 1' Day 1~* Any co morbid condition that' in the view of the attending physician' renders the subject at high risk from treatment complications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Two Short Education Programs for Nonspecific Low Back Pain in a Workers' Health Care Organization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* low back pain patients, with or without referred or radiated pain~* no systemic disease or criteria for referral to surgery~Exclusion Criteria:~* inability to fill out the questionnaires and scales~* bedridden~* rheumatologic inflammatory disease, cancer or fibromyalgia~* suspicion of fibromyalgia~* spinal fracture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-mucinous epithelial ovarian cancer, including primary peritoneal and fallopian tube malignancies, measurable by CT or MRI scan assessed within 4 weeks prior to study entry~* Must have evidence of relapse by CA-125 (2xUpper Limit of Normal) or radiographically within 6 months of most recent platinum-containing chemotherapy. At least one of the lines of chemotherapy must have included a taxane.~* Must have been treated with debulking surgery and at least one line platinum-based chemotherapy;~* Subjects may have received up to four additional lines of chemotherapy after they developed platinum-resistance.~* Subjects must be candidate for repeat paclitaxel treatment~Exclusion Criteria:~* Clinical contraindications to use of paclitaxel, which include:~  1. persistent Grade 2 or greater peripheral neuropathy~ 2. prior hypersensitivity reaction that persisted despite rechallenge with or without desensitization or resulted in bronchospasm or hemodynamic instability or was at least Grade 2 and resulted in medication discontinuation~* Current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas). Note: EOC with prior diagnosis of a low malignant potential tumor that has been surgically resected is acceptable provided the subject did~* Prior radiation therapy is excluded with the exception that it is allowable only if measurable disease for ovarian cancer is completely outside the radiation portal~* Known allergic reaction to a prior monoclonal antibody therapy or have any documented human anti-human antibody (HAHA).~* Previous treatment with MORAb-003 (farletuzumab).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): MORAb-003 (Farletuzumab) Plus Paclitaxel
- 2 (Type: PLACEBO_COMPARATOR): Placebo Plus Paclitaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Older dan 18 years Written Informed Consent Don't use walking adds such as a cane Patients must met El Escorial criteria for probable or definite ALS~Exclusion Criteria:~* Patients who are depending on intermittent or continuous mechanical ventilation Patients who are not able to understand and conform to the instructions Patients who already perform an exercise programme that can compare with our study Patients who have severe cardiopulmonary problems, DM or other problems concerning connective tissue.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven stage III or IV adenocarcinoma of the prostate not potentially curable by surgery or radiotherapy~* Measurable tumors or tumor markers~* No response to antiandrogen withdrawal~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 3 months~Hematopoietic:~* WBC at least 3000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT no greater than 2 times normal~* No hepatic failure~Renal:~* BUN less than 60 mg/dL~* Creatinine no greater than 2.5 mg/dL OR~* Creatinine clearance greater than 60 mL/min~* Blood ammonia normal~* No chronic renal failure~Cardiovascular:~* No severe heart disease~Pulmonary:~* No severe lung disease~Other:~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infection or fever~* No other concurrent serious disease~* No other prior or concurrent malignancy within the past 2 years~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~Chemotherapy:~* At least 4 weeks since prior chemotherapy and recovered~Endocrine therapy:~* At least 4 weeks since prior hormonal therapy and recovered~* Prior corticosteroids for at least 2 months allowed, but must be on stable or decreasing dose during study participation~Radiotherapy:~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy and recovered~Surgery:~* See Disease Characteristics~* At least 4 weeks since prior surgery and recovered~Other:~* At least 4 weeks since prior experimental clinical trial~* No other concurrent therapy for metastatic disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplastons (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with operable rectal cancer~* case discussed at Oxford Colorectal Cancer multi-disciplinary team (MDT) meeting~* willing and able to give informed consent~* willing and able to comply with all trial requirements, in the investigator's opinion~Exclusion Criteria:~* females who are pregnant or lactating~* known intolerance or hypersensitivity to iron, dextran compounds, magnetic tracers or superparamagnetic iron oxide particles (SPIO)~* cancer involvement of anal sphincter complex~* adults who are not able to give consent or are deemed vulnerable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ex-vivo (Type: EXPERIMENTAL): Patients with relatively advanced rectal cancer who are scheduled to undergo radical surgery to excise rectal tumour and mesorectum. They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery. They will then undergo surgery to excise rectal cancer. The excised specimen will be examined using the Sentimag probe and by standard histology to assess for lymph nodes ex-vivo.
- In-vivo (Type: EXPERIMENTAL): Patients with early rectal cancer scheduled to undergo local excision of a rectal tumour by transanal endoscopic microsurgery (TEM). They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery, and have an MRI scan to assess tracer spread. They will then undergo TEM surgery to excise the rectal cancer. During surgery the Sentimag probe will be used to locate the sentinel lymph node so it can be surgically removed. The excised specimen will be examined by standard histology.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Caries Transmission Prevention in Alaska Native Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* primiparous or multiparous pregnant Alaska Native mothers of all ages~* in the last month of pregnancy~* reside in the health service delivery area of the native health corporation, in one of the communities with the highest birth counts from 2002~* eligible for obstetric care from the health corporation~* plan to give birth to their infant in a specified city of Alaska

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Subjects received chlorhexidine mouthwash and xylitol gum , in addition to the usual care specified under the control group
- Control (Type: PLACEBO_COMPARATOR): Subjects received enhanced dental care, health information, toothbrushes and toothpaste. They also received placebo gum and placebo mouth rinse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin and Orofacial Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age or older, males and females~* history of dental and/or maxillofacial treatment/surgery that may cause nerve injury (e.g. root canal treatment, implant placement, deep restorations, tooth extractions, injection of anesthetics)~* patients who score 12 on the validated self-report version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS; Bennett et al. 2005) for extra-oral sites, or 9 for intra-oral sites (the scoring for extra-oral sites is taken as suggested; for intra-oral sites, the 5-point scoring for question 2 has been removed and the score proportionally adjusted, since it is difficult for patients to see color changes in their mouth)~* pain rated 4 or more on a numerical scale (0 being no pain, 10 being the most intense pain imaginable), on a daily basis~* pain lasting more than 6 months~* absence of identifiable organic lesion, inflammation or infection~* normal serum creatinine~* reports that current and previous pain medications failed to provide adequate relief (e.g., analgesic, non-steroidal anti-inflammatories, opioids, antidepressants)~* if currently using medication, acceptance of a wash-out period of at least one week, during which only Tylenol can be used as rescue medication~* able to use the Palm handheld device to report daily pain~Exclusion Criteria:~* lactating, pregnancy (potentially child bearing patients need to have a referral from family physician stating that the patient is not expecting or to be using contraception)~* renal impairment or renal failure (contra-indication to pregabalin)~* congestive heart failure or liver disease~* currently suffering from trigeminal neuralgia~* history of mental disorder, widespread pain or other severe pain conditions that may confound the pain assessment (e.g. depression, chronic fatigue, migraine headaches, fibromyalgia, severe chronic pain conditions)~* intolerance or allergy to gabapentin and pregabalin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Pregabalin capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
- 2 (Type: PLACEBO_COMPARATOR): Placebo capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Physical Therapy With Exercise in Partial-thickness Rotator Cuff Tears

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic partial thickness rotator cuff tear verified with magnetic resonance imaging or ultrasound imaging~* Prescription of multimodal physical therapy with exercise by a clinician other than investigators prior to inclusion in the study~* Covered by the social security system~* Giving informed consent to include in the study~Exclusion Criteria:~* Age of under 50~* Full thickness rotator cuff tear~* Radicular pain~* Glenohumeral osteoarthritis~* Calcific tendonitis~* Adhesive capsulitis~* History of physiotherapy in last 6 months~* Prior surgical treatment~* Contraindication to physical therapy and/or exercises

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Partial thickness rotator cuff tear (Type: None): Patients with symptomatic non-traumatic partial thickness rotator cuff tear treated with multimodal physical therapy with exercise

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have signed an approved informed consent and authorization permitting release of personal health information.~2. Age 18-75 years~3. Pathologically proven recurrent or persistent cervical cancer patients resistant to conventional palliative chemotherapy or radiation therapy~   1. Persistent tumor more than 1cm after initial chemoradiation or radiation therapy~  2. Persistent tumor more than 1cm after chemoradiation, radiation or chemotherapy in recurrent cervical cancer~  3. Metastatic cervical cancer to lung resistant to conventional chemotherapy~4. ECOG performance status 0, 1, 2.~5. Expected survival more than 3 months~6. Patients must have adequate:~   Hematologic function: ANC ≥ 1,500/mcl, Hemoglobin \>10g/dL, platelets ≥ 100,000/mcl Renal function: creatinine ≤ 1.5 x ULN Hepatic function: AST, ALT ≤ 1.5 x ULN,~7. More than 3 weeks from the last day of previous chemotherapy or radiation~Exclusion Criteria:~1. Patients with immune disease or auto-immune disease (ex. rheumatoid arthritis, SLE, immune vasculitis, IDDM)~2. Immune deficiency disease~3. Cancers other than cervical cancer within 5 years~4. Acute myocardial infarction, uncontrolled hypertension~5. Severe allergic disease~6. Severe psychotic disease~7. Those who can be a candidate for curative surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Low dose radiation, Immune cell therapy (Type: EXPERIMENTAL): Combination treatment of low-dose radiation 20cGy every 3 weeks three times and autologous immune cell therapy 2 consecutive weeks 3 times every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues